Biotech Values

[DewDiligence]

ABBV/ENTA will present detailed results of three more phase-3 trials—SAPHIRE-1, SAPHIRE-2, and TURQUOISE-2—in oral presentations at EASL, April 10-12, 2014:

http://finance.yahoo.com/news/enanta-pharmaceuticals-announces-data-presentations-090500374.html

TURQUOISE-2 should receive a lot of attention insofar as it’s the only large phase-3 trial with results for any HCV regimen in 100% cirrhotic patients.

Also at EASL is an oral presentation of a phase-2 trial called M12-999 that tested ABBV/ENTA’s 3-DAA regimen in liver-transplant recipients.

Note: Detailed results of PEARL-3 were presented at CROI in February (#msg-98175067), so PEARL-3 warrants only a poster presentation at EASL.